GVR Report cover Whole Genome Sequencing Market Size, Share & Trends Report

Whole Genome Sequencing Market Size, Share & Trends Analysis Report By Sequencing Type (Large Whole-Genome Sequencing, Small Genome Sequencing), By Applications, By Product, By End Users, By Region, And Segment Forecasts, 2023 To 2030

  • Report ID: GVR453961
  • Number of Pages: 0
  • Format: Electronic (PDF)

WGS is comparatively more recent than targeted sequencing and resequencing, and its implementation is getting simpler as high capacity sequencing technologies are developed. Applications for WGS include genome, microbial resequencing, and de novo genome sequencing. It is projected that it will expand significantly. A rise in the usage of this technology against COVID-19 is expected to drive the market growth. For instance, in March 2022, an article published in Frontiers claimed that WGS may be used to identify SARS-CoV-2 Infection. Furthermore, it helped pediatric oncology patients in differentiating between hospital- and community-acquired infections. Moreover, in December 2022, the Department of Defense developed a SARS-CoV-2 Whole Genome Sequencing Action Plan for the Military Health System in response to the COVID-19 pandemic. In accordance with the strategy, whole genome sequencing will be carried out throughout the MHS by the service laboratories.

This sequencing technology has wide clinical applications. It is attractive for clinical use because it encompasses sections of the genome that can be changed to find differences in the exon regions and uncover causal variants of a disease or disease-causing mutations. The production of WES data on a population level has increased significantly. The Miller Syndrome, Mendelian phenotypes, and complex disease genes were found using the WES, demonstrating its successful applicability in this area.

In addition, companies like Illumina provides microbial WGS as the first NGS technique applicable to the surveillance of infectious diseases. Such technology can deliver quick results and high-quality data. It can also be used to locate, monitor, and address disease outbreaks in a region. WGS is shown to be most useful in research and rarely in therapeutic applications. The market players are also engaged in a number of current projects, which accelerates the adoption of WGS.

Several initiatives by key market players and ongoing technological advancement are likely to create opportunities for market growth. For instance, in November 2022, using Nanopore Genome Sequencing, AI, and Cloud Computing, Stanford Medicine scientists sequence a patient's whole genome in under five hours. They also identified a child with a rare genetic disease in less than eight hours. On the other hand, in November 2021, Illumina and Genetic Alliance announced a USD 120 million global initiative—iHope Genetic Health program. This initiative aims to offer WGS access to various patients impacted by genetic disorders globally.

Whole Genome Sequencing Market Segmentation

Segments

Details

Sequencing Type

Large Whole-Genome Sequencing, Small Genome Sequencing

Product Type

Instrument, Kits, Service

Application

Diagnostics, Drug Discovery and Development, Personalized Medicine, Others

End User

Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Others

Regional

North America, Europe, Asia-Pacific, Latin America, MEA

 

Major players operating in the whole genome sequencing market include GE Healthcare, Thermo Fisher Scientific, Inc., Illumina, Inc., QIAGEN N.V., Agilent Technologies, 10 x Genomics, BGI, Oxford Nanopore, Nebula Genomics, Veritas Genetics, and GENEWIZ amongst others.

 

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon